

Martina Kluth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9470889/publications.pdf>

Version: 2024-02-01

109
papers

2,765
citations

236925

25
h-index

233421

45
g-index

111
all docs

111
docs citations

111
times ranked

4439
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 433-447.	2.8	11
2	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. <i>Cancer Gene Therapy</i> , 2022, 29, 49-61.	4.6	3
3	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. <i>Experimental and Molecular Pathology</i> , 2022, 126, 104762.	2.1	15
4	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211065.	2.1	1
5	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 481-490.	2.2	11
6	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. <i>World Journal of Urology</i> , 2021, 39, 829-837.	2.2	3
7	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 748-758.	5.1	3
8	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â€¦399 Tissue Samples. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110433.	1.9	10
9	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. <i>Biomarker Research</i> , 2021, 9, 7.	6.8	33
10	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. <i>Molecular Medicine</i> , 2021, 27, 16.	4.4	32
11	Y-chromosome loss is frequent in male renal tumors. <i>Annals of Translational Medicine</i> , 2021, 9, 209-209.	1.7	13
12	Napsin A Expression in Human Tumors and Normal Tissues. <i>Pathology and Oncology Research</i> , 2021, 27, 613099.	1.9	12
13	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naïve clear cell renal cell cancer. <i>International Urology and Nephrology</i> , 2021, 53, 2493-2503.	1.4	11
14	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. <i>Biomedicines</i> , 2021, 9, 397.	3.2	42
15	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. <i>Biomarker Research</i> , 2021, 9, 44.	6.8	30
16	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. <i>Acta OncolÃ³gica</i> , 2021, 60, 1210-1217.	1.8	10
17	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
18	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	High mitochondrial content is associated with breast cancer aggressiveness. <i>Molecular and Clinical Oncology</i> , 2021, 15, 203.	1.0	3
20	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. <i>PeerJ</i> , 2021, 9, e11905.	2.0	4
21	Pattern of placental alkaline phosphatase (<scp>PLAP</scp>) expression in human tumors: a tissue microarray study on 12,381 tumors. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 577-589.	3.0	12
22	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. <i>Human Pathology</i> , 2021, 115, 19-36.	2.0	19
23	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151793.	1.3	11
24	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. <i>Medical Molecular Morphology</i> , 2021, 54, 156-165.	1.0	9
25	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. <i>Pathology Research and Practice</i> , 2021, 228, 153663.	2.3	11
26	6q deletion is frequent but unrelated to patient prognosis in breast cancer. <i>Breast Cancer</i> , 2021, , 1.	2.9	1
27	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 129-138.	4.6	19
28	High homogeneity of mismatch repair deficiency in advanced prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 745-752.	2.8	17
29	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 43.e13-43.e20.	1.6	8
30	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2185-2196.	2.2	10
31	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. <i>BioMed Research International</i> , 2020, 2020, 1-13.	1.9	7
32	High B7-3 expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , 2020, 70, 733-742.	1.3	16
33	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2020, 20, 1220.	2.6	12
34	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 625-636.	2.8	6
35	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 128.	1.9	3
36	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. <i>International Journal of Cancer</i> , 2020, 147, 575-583.	5.1	4

#	ARTICLE	IF	CITATIONS
37	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. <i>Endocrine Pathology</i> , 2020, 31, 182-189.	9.0	15
38	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3997-4006.	1.5	20
39	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , 2020, 80, 1097-1107.	2.3	10
40	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 488-495.	1.6	19
41	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 669-675.	1.4	24
42	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 605.e1-605.e8.	1.6	3
43	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. <i>Oncotarget</i> , 2020, 11, 237-249.	1.8	19
44	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. <i>Oncotarget</i> , 2020, 11, 1007-1016.	1.8	14
45	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019, 18, 1497-1502.	1.8	7
46	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. <i>Cancer Biology and Medicine</i> , 2019, 16, 319.	3.0	2
47	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. <i>Oncology Letters</i> , 2019, 17, 3826-3834.	1.8	19
48	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 193.	2.6	24
49	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , 2019, 79, 302-311.	2.3	4
50	5q21 deletion is often heterogeneous in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 509-515.	2.8	4
51	A nuclear shift of GSK3 ^β protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , 2019, 10, 1729-1744.	1.8	2
52	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. <i>Oncotarget</i> , 2019, 10, 4973-4986.	1.8	5
53	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , 2019, 10, 5439-5453.	1.8	22
54	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , 2018, 18, 37.	2.6	16

#	ARTICLE	IF	CITATIONS
55	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 877-882.	2.2	26
56	Upregulation of centromere protein F is linked to aggressive prostate cancers. <i>Cancer Management and Research</i> , 2018, Volume 10, 5491-5504.	1.9	17
57	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , 2018, 8, 17535.	3.3	23
58	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. <i>BMC Cancer</i> , 2018, 18, 1209.	2.6	28
59	Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5909-5917.	1.9	3
60	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , 2018, 34, 996-1011.e8.	16.8	190
61	High concordance of TMPRSS2-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , 2018, 16, 6238-6244.	1.8	3
62	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e19-531.e25.	1.6	17
63	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2018, 105, 50-56.	2.1	6
64	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 504-512.	2.8	35
65	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. <i>BMC Cancer</i> , 2018, 18, 612.	2.6	19
66	Apurinic/aprimidinic endonuclease 1 (APE1/Ref1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. <i>Molecular Carcinogenesis</i> , 2017, 56, 2135-2145.	2.7	19
67	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , 2017, 19, 279-287.	5.3	16
68	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. <i>Prostate</i> , 2017, 77, 1528-1538.	2.3	16
69	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , 2017, 38, 1180-1187.	2.8	15
70	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. <i>Neoplasia</i> , 2017, 19, 707-715.	5.3	65
71	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. <i>Scientific Reports</i> , 2017, 7, 2056.	3.3	27
72	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. <i>Carcinogenesis</i> , 2017, 38, 19-27.	2.8	51

#	ARTICLE	IF	CITATIONS
73	High-Level \hat{I}^3 -Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 286.	4.1	30
74	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. <i>BMC Cancer</i> , 2017, 17, 504.	2.6	9
75	Deletion of 8p is an independent prognostic parameter in prostate cancer. <i>Oncotarget</i> , 2017, 8, 379-392.	1.8	36
76	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2017, 8, 31494-31508.	1.8	10
77	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , 2017, 8, 108923-108935.	1.8	26
78	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , 2016, 76, 259-272.	2.3	27
79	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2802-2811.	7.0	21
80	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. <i>Tumor Biology</i> , 2016, 37, 12655-12663.	1.8	20
81	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. <i>BMC Cancer</i> , 2016, 16, 641.	2.6	24
82	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , 2016, 138, 1199-1206.	5.1	30
83	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , 2016, 48, 102-110.	2.0	18
84	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. <i>Oncotarget</i> , 2016, 7, 81322-81331.	1.8	31
85	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. <i>Oncotarget</i> , 2016, 7, 86339-86349.	1.8	24
86	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. <i>Oncotarget</i> , 2016, 7, 3897-3904.	1.8	8
87	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. <i>International Journal of Cancer</i> , 2015, 137, 2354-2363.	5.1	39
88	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , 2015, 10, e0128525.	2.5	26
89	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0134614.	2.5	16
90	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. <i>International Journal of Oncology</i> , 2015, 46, 1637-1642.	3.3	13

#	ARTICLE	IF	CITATIONS
91	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , 2015, 34, 1211-1220.	2.6	12
92	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8591-8606.	4.1	4
93	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2015, 98, 419-426.	2.1	26
94	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , 2015, 15, 538.	2.6	30
95	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3471-3479.	7.0	43
96	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. <i>Oncotarget</i> , 2015, 6, 8377-8387.	1.8	44
97	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2015, 6, 27966-27979.	1.8	30
98	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 5027-5027.	1.6	0
99	High nuclear karyopherin $\beta 2$ expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Modern Pathology</i> , 2014, 27, 96-106.	5.5	25
100	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. <i>Modern Pathology</i> , 2014, 27, 1612-1620.	5.5	69
101	Clinical significance of different types of <i>p53</i> gene alteration in surgically treated prostate cancer. <i>International Journal of Cancer</i> , 2014, 135, 1369-1380.	5.1	95
102	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. <i>Microarrays (Basel, Switzerland)</i> , 2014, 3, 137-158.	1.4	2
103	β -III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. <i>American Journal of Pathology</i> , 2014, 184, 609-617.	3.8	48
104	Reduced membranous MET expression is linked to bladder cancer progression. <i>Cancer Genetics</i> , 2014, 207, 147-152.	0.4	5
105	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. <i>Prostate</i> , 2013, 73, 1690-1698.	2.3	38
106	Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer. <i>Cancer Cell</i> , 2013, 23, 159-170.	16.8	292
107	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. <i>Modern Pathology</i> , 2013, 26, 975-983.	5.5	127
108	Marked heterogeneity of ERG expression in large primary prostate cancers. <i>Modern Pathology</i> , 2013, 26, 106-116.	5.5	62

#	ARTICLE	IF	CITATIONS
109	<i>CHD1</i> Is a 5q21 Tumor Suppressor Required for <i>ERG</i> Rearrangement in Prostate Cancer. <i>Cancer Research</i> , 2013, 73, 2795-2805.	0.9	188